Deeksha Bali

Deeksha Bali

Auto-generated profile, based on publicly available information

Deeksha Bali

Biochemical Genetics Laboratory, Duke University Health System, Durham, NC 27710, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
FPFrancesco Puzzo
Francesco Puzzo
PCPasqualina Colella
Pasqualina Colella
MBMaria Grazia Biferi
Maria Grazia Biferi
DBDeeksha Bali
Deeksha Bali
NPNicole K. Paulk
Nicole K. Paulk
FMFederico Mingozzi
Federico Mingozzi
Liver delivery of engineered GAA transgenes to mice with Pompe disease rescued glycogen accumulation in multiple tissues.

14 November 2025 in Science Advances
Verified
Journal Article
Open access
RGRebecca A. Gibson
Rebecca A. Gibson
WJWilliam R. Jeck
William R. Jeck
RGRebecca Gould
Rebecca Gould
NJNeha Jumani
Neha Jumani
SCSu Jin Choi
Su Jin Choi
PKPriya Kishnani
Priya Kishnani
Glycogen storage disease (GSD) type IX γ2 is a rare inborn error of metabolism where a defect in glycogenolysis leads to the inability to break down glycogen in the liver. Patients with GSD IX γ2 develop hypoglycemia and advanced liver disease, placing them at risk for liver transplantation. This study evaluates the efficacy of liver-directed AAV gene therapy in a murine model of GSD IX γ2. Phkg2 −/− mice underwent treatment with AAV gene therapy (AAV9-LSP- mPhkg2 , 5 × 10 12 vg/kg, intravenous delivery) at ages 3 or 6 months and were treated for either 2 weeks, 3 months, or 12 months. Results demonstrated that AAV gene therapy reduced GSD IX γ2 disease burden across all primary end points. AAV gene therapy also persisted across the mouse lifespan and reduced preexisting liver fibrosis. This work provides preclinical data supporting AAV gene therapy as a definitive treatment for GSD IX γ2.

1 April 2021 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
RMRoberto Mendez
Roberto Mendez
DBDeeksha Bali
Deeksha Bali
ASAshlee Stiles
Ashlee Stiles
HZHaoyue Zhang
Haoyue Zhang
CLCindy Li
Cindy Li
SYSarah Young
Sarah Young

23 April 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
MCMolly M. Crenshaw
Molly M. Crenshaw
EBErica Burner-Nading
Erica Burner-Nading
JMJamie Mills
Jamie Mills
EHErin Huggins
Erin Huggins
NKNatalie Krohl
Natalie Krohl
JCJennifer L. Cohen
Jennifer L. Cohen
Pompe disease, a lysosomal disease, was added to the Recommended Uniform Screening Panel in 2015, and it has been included in the newborn screening (NBS) panel in North Carolina (NC) since February 2023. Across the world, the approach to NBS for Pompe disease varies. This study adds to the literature 20 months of population level health data from NC regarding infants who screened positive for Pompe disease via NBS. Fifty-two of 228,474 (0.02%) infants screened positive for Pompe disease, and after diagnostic testing, 18 (35%) were diagnosed with presumed late-onset Pompe disease (LOPD), resulting in a higher than previously reported incidence of 1 in 12,693. No infants with the infantile onset form of disease were identified at the time of data closure. While seasonal variations existed in the absolute value of dried blood spot (DBS) acid α-glucosidase (GAA) enzyme activity, this was successfully controlled for using cutoffs defined by the percent of the daily median of enzyme activity. None of the following parameters correlated with the final clinical designation in a statistically significant manner: percent of the daily median DBS GAA enzyme activity, creatine/creatinine/GAA ratio, nor birthweight. The use of the creatine/creatinine/GAA ratio has been eliminated in NC because of these data. The GAA/α-L-iduronidase ratio was statistically significant in its association to final clinical designations of Pompe disease, and thus provides an opportunity to further refine NBS for Pompe disease in NC. The mean GAA enzyme activity was also statistically significantly different based on the age of NBS sample collection. We propose two algorithms that outline 1) an approach to enable timely treatment of the infantile onset form of Pompe disease; and 2) a more detailed approach for reaching a clinical designation after a positive NBS for Pompe disease. Opportunities for growth, remaining questions, and responsible stewardship of our public health resources are discussed.

17 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
AIApoorva K. Iyengar
Apoorva K. Iyengar
XZXue Zou
Xue Zou
JDJian Dai
Jian Dai
RFRhodricia A. Francis
Rhodricia A. Francis
ASAlexias Safi
Alexias Safi
TRTimothy E. Reddy
Timothy E. Reddy
Delayed diagnosis of Mendelian disease substantially prevents early therapeutic intervention that could improve symptoms and prognosis. One major contributing challenge is the functional interpretation of non-coding variants that cause disease by altering splicing and/or gene expression. We identified two siblings with glycogen storage disease (GSD) type IX γ2, both of whom had a classic clinical presentation, enzyme deficiency, and a known pathogenic splice acceptor variant on one allele of PHKG2 . Despite the autosomal recessive nature of the disease, no variant on the second allele was identified by gene panel sequencing. To identify a potential missing second pathogenic variant, we completed whole genome sequencing (WGS) and detected putative deep intronic splicing variant in PHKG2 in both siblings. We confirmed the functional splicing effects of this variant using short-read and long-read RNA-seq on patient blood and a HEK293T cell model in which we installed the variant using CRISPR editing. Using the cell model, we demonstrated multiple biochemical and cellular impacts that are consistent with GSD IX γ2, and a reversal of aberrant splicing using antisense splice-switching oligonucleotides. In doing so, we demonstrate a novel and robust pathway for detecting, validating, and reversing the impacts of novel non-coding causes of rare disease.